Ikena Oncology (IKNA)

• Market cap: $68M
• 1 day: -2.08%
• 5 days: 9.30%
• 1 month: -2.76%
• 3 months: -17.06%
• 6 months: -16.57%
• Year to date: -14.55%
• 1 year: -3.42%
• 5 years: -95.59%
• 10 years: -95.59%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.

Employees: 43

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

200% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 3 (+2) [Q4]

11.19% more ownership

Funds ownership: 67.57% [Q3] → 78.77% (+11.19%) [Q4]

6% more capital invested

Capital invested by funds: $49.1M [Q3] → $52M (+$2.86M) [Q4]

7% less funds holding

Funds holding: 57 [Q3] → 53 (-4) [Q4]

36% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 11

55% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 20